Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAS1R3 | Q7RTX0 | 5/20 | 0.37 |
| ▸ | TAS1R1 | Q7RTX1 | 5/20 | 0.37 |
| ▸ | ABCB1 | P08183 | 4/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19946426 | 1.00 | TAS1R3 (0.37) | TAS1R3TAS1R1ABCB1CYP3A4HPGD | |
| SCHEMBL29684859 | 0.93 | ABCB1 (0.36) | TAS1R3TAS1R1ABCB1CYP3A4HPGD | |
| SCHEMBL2683648 | 0.93 | ABCB1 (0.36) | TAS1R3TAS1R1ABCB1CYP3A4HPGD | |
| SCHEMBL668634 | 0.93 | ABCB1 (0.36) | TAS1R3TAS1R1ABCB1CYP3A4HPGD | |
| SCHEMBL668095 | 0.86 | ABCB1 (0.38) | ABCB1CYP3A4HPGD | |
| SCHEMBL29685124 | 0.86 | ABCB1 (0.38) | ABCB1CYP3A4HPGD | |
| SCHEMBL9903268 | 0.85 | ALDH1A1 (0.38) | TAS1R3TAS1R1ABCB1CYP3A4HPGD | |
| SCHEMBL668085 | 0.84 | ABCB1 (0.38) | TAS1R3TAS1R1ABCB1CYP3A4HPGD | |
| SCHEMBL2684734 | 0.84 | ABCB1 (0.38) | TAS1R3TAS1R1ABCB1CYP3A4HPGD | |
| SCHEMBL29786240 | 0.84 | ABCB1 (0.38) | TAS1R3TAS1R1ABCB1CYP3A4HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200270225-A1 | Chiral Diacylhydrazine Ligands for Modulating the Expression of Exogenous Genes via an Ecdysone Receptor Complex | INTREXON CORPORATION (US) | 2020-08-27 | — | — | US | claimed |
| EP-3357904-A1 | CHIRAL DIACHYLHYDRAZINE LIGANDS FOR MODULATING THE EXPRESSION OF EXOGENOUS GENES VIA AN ECDYSONE RECEPTOR COMPLEX | Intrexon Corporation (US) | 2018-08-08 | — | — | EP | claimed |
| US-20090163592-A1 | Chiral diacylhydrazine ligands for modulating the expression of exogenous genes via an ecdysone receptor complex | INTREXON CORPORATION (US) | 2009-06-25 | — | — | US | claimed |
| EP-3357904-B1 | CHIRAL DIACHYLHYDRAZINE LIGANDS FOR MODULATING THE EXPRESSION OF EXOGENOUS GENES VIA AN ECDYSONE RECEPTOR COMPLEX | PRECIGEN INC (US) | 2022-07-06 | — | — | EP | disclosed |
| EP-3357904-B1 | CHIRAL DIACHYLHYDRAZINE LIGANDS FOR MODULATING THE EXPRESSION OF EXOGENOUS GENES VIA AN ECDYSONE RECEPTOR COMPLEX | PRECIGEN INC (US) | 2022-07-06 | — | — | EP | disclosed |
| US-20200270225-A1 | Chiral Diacylhydrazine Ligands for Modulating the Expression of Exogenous Genes via an Ecdysone Receptor Complex | INTREXON CORPORATION (US) | 2020-08-27 | — | — | US | disclosed |
| US-20200270225-A1 | Chiral Diacylhydrazine Ligands for Modulating the Expression of Exogenous Genes via an Ecdysone Receptor Complex | INTREXON CORPORATION (US) | 2020-08-27 | — | — | US | disclosed |
| US-10633361-B2 | Chiral diacylhydrazine ligands for modulating the expression of exogenous genes via an ecdysone receptor complex | INTREXON CORPORATION (US) | 2020-04-28 | — | — | US | disclosed |
| US-10633361-B2 | Chiral diacylhydrazine ligands for modulating the expression of exogenous genes via an ecdysone receptor complex | INTREXON CORPORATION (US) | 2020-04-28 | — | — | US | disclosed |
| EP-3357904-A1 | CHIRAL DIACHYLHYDRAZINE LIGANDS FOR MODULATING THE EXPRESSION OF EXOGENOUS GENES VIA AN ECDYSONE RECEPTOR COMPLEX | Intrexon Corporation (US) | 2018-08-08 | — | — | EP | disclosed |
| EP-3357904-A1 | CHIRAL DIACHYLHYDRAZINE LIGANDS FOR MODULATING THE EXPRESSION OF EXOGENOUS GENES VIA AN ECDYSONE RECEPTOR COMPLEX | Intrexon Corporation (US) | 2018-08-08 | — | — | EP | disclosed |
| US-20120116090-A1 | Chiral Diacylhydrazine Ligands for Modulating the Expression of Exogenous Genes via an Ecdysone Receptor Complex | INTREXON CORPORATION (US) | 2012-05-10 | — | — | US | disclosed |
| US-20120116090-A1 | Chiral Diacylhydrazine Ligands for Modulating the Expression of Exogenous Genes via an Ecdysone Receptor Complex | INTREXON CORPORATION (US) | 2012-05-10 | — | — | US | disclosed |
| US-8076517-B2 | Chiral diacylhydrazine ligands for modulating the expression of exogenous genes via an ecdysone receptor complex | INTREXON CORPORATION (US) | 2011-12-13 | — | — | US | disclosed |
| US-8076517-B2 | Chiral diacylhydrazine ligands for modulating the expression of exogenous genes via an ecdysone receptor complex | INTREXON CORPORATION (US) | 2011-12-13 | — | — | US | disclosed |
| US-8076517-B2 | Chiral diacylhydrazine ligands for modulating the expression of exogenous genes via an ecdysone receptor complex | INTREXON CORPORATION (US) | 2011-12-13 | — | — | US | disclosed |
| US-20090163592-A1 | Chiral diacylhydrazine ligands for modulating the expression of exogenous genes via an ecdysone receptor complex | INTREXON CORPORATION (US) | 2009-06-25 | — | — | US | disclosed |
| US-20090163592-A1 | Chiral diacylhydrazine ligands for modulating the expression of exogenous genes via an ecdysone receptor complex | INTREXON CORPORATION (US) | 2009-06-25 | — | — | US | disclosed |
| US-20090163592-A1 | Chiral diacylhydrazine ligands for modulating the expression of exogenous genes via an ecdysone receptor complex | INTREXON CORPORATION (US) | 2009-06-25 | — | — | US | disclosed |
| WO-2008153801-A1 | CHIRAL DIACHYLHYDRAZINE LIGANDS FOR MODULATING THE EXPRESSION OF EXOGENOUS GENES VIA AN ECDYSONE RECEPTOR COMPLEX | INTREXON CORPORATION (US) | 2008-12-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090163592-A1 | Chiral diacylhydrazine ligands for modulating the expression of exogenous genes via an ecdysone receptor complex | NR2E3, CRYZ, TCF12 | TAS1R3 3889/4885TAS1R1 4166/4885ABCB1 692/4885 |
| US-20200270225-A1 | Chiral Diacylhydrazine Ligands for Modulating the Expression of Exogenous Genes via an Ecdysone Receptor Complex | NR2E3, CRYZ, TCF12 | TAS1R3 3889/4885TAS1R1 4166/4885ABCB1 692/4885 |
| US-10633361-B2 | Chiral diacylhydrazine ligands for modulating the expression of exogenous genes via an ecdysone receptor complex | NR2E3, CRYZ, TCF12 | TAS1R3 3889/4885TAS1R1 4166/4885ABCB1 692/4885 |
| US-20120116090-A1 | Chiral Diacylhydrazine Ligands for Modulating the Expression of Exogenous Genes via an Ecdysone Receptor Complex | NR2E3, CRYZ, TCF12 | TAS1R3 3889/4885TAS1R1 4166/4885ABCB1 692/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.